MILFORD, MA--(Marketwired - October 24, 2013) - PLC Systems Inc. (PLCSF), a company focused on innovative medical device technologies, today announced that its lead product, RenalGuard®, will be displayed at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting. The meeting is being held from October 27 to November 1, 2013 at the Moscone Center in San Francisco, CA.
RenalGuard will be displayed at PLC's booth (#535) and the booth of ACIST Medical Systems (#1917), PLC's distributor in France, Germany, Belgium and the Netherlands.
PLC management will be available to meet with members of the investment community during the conference. Investors may visit PLC's booth, or call Lisa Caperelli at 215-340-1241 to schedule a one-on-one meeting.
TCT is sponsored by the Cardiovascular Research Foundation, and more than 12,000 clinicians and professionals from around the world are expected to attend this year's event. Each year TCT attracts a large international audience, which provides us with increased exposure in countries where we are currently selling RenalGuard, including Europe, South America and the Middle East.
About PLC Systems Inc.
PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing Contrast-Induced Acute Kidney Injury (CI-AKI). RenalGuard is being studied in a pivotal trial in the U.S., as part of the FDA approval process. For more information, visit www.plcmed.com, or connect with the Company on Facebook, Twitter, LinkedIn, YouTube and Google+.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.
PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.